Antipsychotic-induced weight gain.
Novel 'atypical' antipsychotic drugs represent a substantial improvement on older 'typical' drugs. However, clinical experience has shown that some, but not all, of these drugs can induce substantial weight gain. This interferes with compliance with drug taking and has expected effects on morbidity and mortality. In this review, we summarize current thinking on: (i) the extent to which different 'atypical' drugs induce weight gain; (ii) the possible roles of various neurotransmitters and neuropeptides in this adverse drug reaction; and (iii) the state of development of animal models in this area. We also outline major areas for future research.
Goudie
A J
AJ
School of Psychology, Liverpool University, Liverpool, UK. ajg@liverpool.ac.uk
Cooper
G D
GD
Halford
J C G
JC
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism; D001569:Benzodiazepines / Q000009:adverse effects; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D009479:Neuropeptides / Q000502:physiology; D009765:Obesity / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D000077152:Olanzapine; D051381:Rats; D017982:Receptors, Biogenic Amine / Q000502:physiology; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology
D014150:Antipsychotic Agents; D009479:Neuropeptides; D017982:Receptors, Biogenic Amine; D001569:Benzodiazepines; D000077152:Olanzapine